SUPERNUS PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
SUPN$27.62+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $128,448 | $69,331 |
| Marketable securities | 180,222 | 384,281 |
| Accounts receivable, net | 187,802 | 142,077 |
| Inventories, net | 82,385 | 54,293 |
| Prepaid expenses and other current assets | 65,325 | 36,088 |
| Total current assets | 644,182 | 686,070 |
| Restricted cash | 1,450 | — |
| Property and equipment, net | 10,531 | 11,545 |
| Intangible assets, net | 569,456 | 521,912 |
| Goodwill | 124,882 | 117,019 |
| Deferred income tax assets, net | 38,351 | — |
| Other assets | 63,796 | 31,527 |
| Total assets | $1,452,648 | $1,368,073 |
| Liabilities and stockholders' equity | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $107,800 | $76,352 |
| Accrued product returns and rebates | 161,097 | 168,705 |
| Contingent consideration, current portion | 31,052 | 47,340 |
| Other current liabilities | 38,222 | — |
| Total current liabilities | 338,171 | 292,397 |
| Contingent consideration, long-term | 206 | — |
| Operating lease liabilities, long-term | 30,365 | 27,382 |
| Deferred income tax liabilities, net | — | 4,961 |
| Other liabilities | 22,192 | 7,600 |
| Total liabilities | 390,934 | 332,340 |
| Commitments and contingencies (Note 18) | ||
| Stockholders' equity | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 57,457,462 and 55,743,095 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 57 | 56 |
| Additional paid-in capital | 543,825 | 479,440 |
| Accumulated other comprehensive loss, net of tax | (44) | (189) |
| Retained earnings | 517,876 | 556,426 |
| Total stockholders' equity | 1,061,714 | 1,035,733 |
| Total liabilities and stockholders' equity | $1,452,648 | $1,368,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.